March 28, 2024 – Medtronic introduced that the U.S. Meals and Drug Administration (FDA) has authorized the Evolut™ FX+ Transcatheter Aortic Valve Alternative System (TAVR) for the therapy of symptomatic extreme aortic stenosis. The newest Evolut FX+ TAVR system retains the valve efficiency advantages of the older Evolut TAVR platform and is designed to facilitate coronary entry. […]